MXPA05011568A - Uso de irinotecan para el tratamiento de cancer recurrente de mama. - Google Patents

Uso de irinotecan para el tratamiento de cancer recurrente de mama.

Info

Publication number
MXPA05011568A
MXPA05011568A MXPA05011568A MXPA05011568A MXPA05011568A MX PA05011568 A MXPA05011568 A MX PA05011568A MX PA05011568 A MXPA05011568 A MX PA05011568A MX PA05011568 A MXPA05011568 A MX PA05011568A MX PA05011568 A MXPA05011568 A MX PA05011568A
Authority
MX
Mexico
Prior art keywords
irinotecan
breast cancer
treatment
resistant breast
fluoropyrimidine
Prior art date
Application number
MXPA05011568A
Other languages
English (en)
Inventor
Larry J Schaaf
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of MXPA05011568A publication Critical patent/MXPA05011568A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a un metodo para tratar cancer de mama localmente avanzado o metastatico en un paciente que ha demostrado fracaso de tratamientos anteriores con una antraciclina, con un taxano y con una fluoropirimidina, que comprende administrar una cantidad terapeuticamente eficaz de irinotecan.
MXPA05011568A 2003-04-28 2004-04-20 Uso de irinotecan para el tratamiento de cancer recurrente de mama. MXPA05011568A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46622203P 2003-04-28 2003-04-28
PCT/IB2004/001395 WO2004096223A1 (en) 2003-04-28 2004-04-20 Use of irinotecan for treatment of resistant breast cancer

Publications (1)

Publication Number Publication Date
MXPA05011568A true MXPA05011568A (es) 2005-12-14

Family

ID=33418353

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011568A MXPA05011568A (es) 2003-04-28 2004-04-20 Uso de irinotecan para el tratamiento de cancer recurrente de mama.

Country Status (13)

Country Link
US (1) US20040266704A1 (es)
EP (1) EP1620099A1 (es)
JP (1) JP2006524678A (es)
KR (1) KR20050116166A (es)
CN (1) CN1774249A (es)
AU (1) AU2004233743A1 (es)
BR (1) BRPI0409870A (es)
CA (1) CA2523152A1 (es)
CL (1) CL2004000888A1 (es)
MX (1) MXPA05011568A (es)
TW (1) TW200509925A (es)
WO (1) WO2004096223A1 (es)
ZA (1) ZA200508696B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107456456A (zh) * 2016-06-03 2017-12-12 江苏恒瑞医药股份有限公司 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
IL146872A0 (en) * 1999-06-03 2002-08-14 Methods and compositions for modulating cell proliferation and cell death

Also Published As

Publication number Publication date
TW200509925A (en) 2005-03-16
WO2004096223A1 (en) 2004-11-11
AU2004233743A1 (en) 2004-11-11
ZA200508696B (en) 2006-07-26
EP1620099A1 (en) 2006-02-01
BRPI0409870A (pt) 2006-05-16
KR20050116166A (ko) 2005-12-09
CL2004000888A1 (es) 2005-03-18
CN1774249A (zh) 2006-05-17
JP2006524678A (ja) 2006-11-02
CA2523152A1 (en) 2004-11-11
US20040266704A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
SI1913947T1 (sl) Kombinirana terapija za zdravljenje raka
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
HK1120441A1 (en) Drugs for treatment of ovarian cancer
MX336710B (es) Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades.
WO2009067397A3 (en) Treatment for solid tumors
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
TW201129380A (en) Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1
RS105304A (en) Methods of treating angiogenesis,tumor growth,and metastasis
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
MY146533A (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
WO2007134203A3 (en) Anticancer treatments with a combination of docetaxel and ecteinascidin
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
MXPA05011568A (es) Uso de irinotecan para el tratamiento de cancer recurrente de mama.
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
WO2006069217A3 (en) Small molecule cyclin d1 ablative agents
MXPA04009012A (es) Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.
MXPA05008879A (es) Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
IL191690A0 (en) Therapy of malignant neoplasias